Anemia in Hemodialysis Patients in Gherian Central Hospital.
DOI:
https://doi.org/10.54361/Abstract
Anemia is frequent complication in hemodialysis patients. Compared to conventional hemodialysis (CHD), short daily hemodialysis (sDHD) has been reported to be effective in Gherian central hospital. The aim of the present study was to determine whether (sDHD) could improve anemia and quality of life (QOL) for those patients with end-stage renal disease. Twenty seven patients (16 males /11 females) were converted from CHD to sDHD in our study. In this study, In Gherian Central Hospital, all patients undergoing conventional hemodialysis (CHD) have complications including anemia and impaired quality of life (QOL). However, were observed the (CHD) could not improve clinical outcomes in patients with End-stage renal disease (ESRD). According to these studies (CHD) could not improve the state of anemia in males and females N=(27), and also not increase or improvement the quality of life (QOL ) scores. However, those results were obtained from hemodialysis patients in our study under good control and follow up in Gherian Central Hospital. This study shows that action of conventional hemodialysis ( CHD ) was associated with significantly difference in hemoglobin concentration by erythropoietin treatment in males and females (P < 0.05) was considered to be significant.
Downloads
References
Abramson JL, Jurkovitz CT, Vaccarino V, et al. Chronic Kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int 2003; 64:610.
Allen N, Schwartz D, Komenda P, Pauly RP, Zimmerman D, Tanna G, et al. International practice patterns and factors associated with non-conventional hemodialysis utilization. BMC Nephrol 2011; 12: 66, doi: 10.1186/1471-2369-12-66.(Links).
Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000; 20:345.
Collins AJ, Li S, St peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12:2465.
Centers for Medicare and Medicaid Services, Kidney R. 2005 Annual Report: ESRD Clinical Performance Measures Project. Am J Kidney Dis 2006; 48: S1.
DePalma JR, Pecker EA, Gordon A, Maxwell MH. Anew compact automatic home hemodialysis system. Trans Am Soc Artif Intern Organs 1968; 14: 152-159.(Links).
Drueke TB, Locatelli F, Clyne N, et al. Normalzation of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071.
Eschbach JW. Erythropoietin 1991--an overview. Am J Kidney Dis 1991; 18:3.
Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111:992.
Gandra SR, Finkelstein FO, Bennett AV, et al. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systemic review. Am kidney Dis 2010; 55:519.
Hariharan S, Yang H. Introduction. Am J Kidney Dis. 2006; 47:S1.
Ifudu O, Uribarri J, Rajwani I, et al. Adequacy of dialysis and differences in hematocrit among dialysis facilities. Am J Kidney Dis 2000; 36:1166.
Jurkovitz CT, Abramson JL, Vaccarino LV, et al. Association of high serum creatinine and anemia increase the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities(ARIC) study. J Am Soc Nephrol 2003; 14:2919.
Kazmi WH, Kausz AT, Khan S, et al. Anemia: an early complication of chronic renal insufficiency. AM j Kidney Dis 2001; 38:803.
KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2:288.
Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34:125.
Lewis EF, Pfeffer MA, Feng A, et al. Darbepoetin alfa impact on health status in diabetes patients eith kidney disease: a randomized trial. Clin J Am Soc Nephrol 2001; 6:845.
Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10:610.
McClellan WM, Flanders WD, Langston RD, et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002; 13:1928.
Muirhead N, Bargman J, Burgess E, et al. Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 1995; 26:S1.
Obrador GT, Roberts T, St Peter WL, et al. Trends in anemia at initiation of dialysis in the United states. Kidney Int 2001; 60:1875.
Panichi V, Scatena A, Paoletti S, Migliori M. Impact of dialysis technique on renal anemia. Contrib Nephrol 2011; 171:261-265, doi: 10.1159/000327341.(Links).
Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomtic heart disease. J Am Soc Nephrol 2005; 16:2180.
Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of Darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 200; 361:2019.
Punal Rioboo J, Sanchez- Iriso E, Ruano-Ravina A, Varela Lema ML, Sanchez-Guisande D, Gonzalez-Rodriguez L, et al. Short daily versus conventional hemodialysis quality of life: a cross-sectional multicentric study in Spain. Blood Purif 2009; 28: 159-164, doi: 10.1159/000227784.(Links).
Sarnak MJ, Tighiouart H, Manjunath G, et al. Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk in communities(ARIC) study. J Am Coll Cardiol 2002; 40:27.
Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085.
World Health Organization. Nutritional Anaemias :Report of a WHO Scientific Group. Geneva, Switzerland: World Health Organization; 1968.
Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999; 10:1309.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 Ramadan Ali Alshames, Ashraf Fatah Alzalitni, Abdulbasit aljale (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
